Letrozole is approved by the FDA for the adjuvant treatment of early - stage breast cancer in postmenopausal women who have already been treated with 5 years of tamoxifentherapy.
A recent study of women whose cancer was treated with tamoxifentherapy and who were also taking the antidepressant paroxetine demonstrates the potential problems of using these drugs: the patients increased their risk of death by 91 %.